Enzymotec’s technology and research and development platform supports product development for both of our operating segments by leveraging our core scientific expertise in lipid and enzymatic technologies. Our research and development (R&D) activities are directed towards developing bio-functional lipid ingredients and final products. In order to achieve this goal, we develop and utilize sophisticated proprietary technologies and know-how that enable us to extract lipids from natural sources, separate and analyze lipid molecules, and use enzymes to synthesize lipid molecules familiar to the body. We have established a proprietary toolset that allows us to efficiently transform lipids from natural raw materials into those that have unique structural and functional characteristics.
We conduct clinical and pre-clinical studies to support the safety and efficacy of our products and their ingredients, to expand known benefits, and to uncover new benefits of our products. We are committed to conducting all of our research activities according to good clinical practice (GCP) guidelines ensuring high quality and reliable results.
To date, we have successfully completed 14 clinical trials demonstrating our products’ health benefits, and have published these data in 20 peer-reviewed articles.
Enzymotec’s R&D capabilities extend also into the regulatory affairs field. The selling and marketing of our products are subject to comprehensive laws, regulations, and standards enforced by various local, regional, and national regulatory bodies, including the FDA in the United States, the European Commission in the European Union, the Therapeutic Goods Administration (TGA) in Australia, the Ministry of Health in China, and the Ministry of Health in Israel. Our extensive global regulatory expertise has enabled us to launch products in over 30 markets.
We currently have over 150 patents and patent applications worldwide covering our manufacturing processes, product compositions, and different intended uses of the products.
We believe that our integrated platform of technology, research and development, and manufacturing will continue to serve as an engine of growth that feeds our product pipeline.